Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Diagens Biotechnology Co ROE % Adjusted to Book Value Chart
Hangzhou Diagens Biotechnology Co Annual Data
Trend
Dec23
Dec24
Dec25
ROE % Adjusted to Book Value
0.00
0.00
0.00
Hangzhou Diagens Biotechnology Co Quarterly Data
Dec23
Dec24
Sep25
Dec25
Jun26
ROE % Adjusted to Book Value
0.00
0.00
0.00
0.00
0.00
HKSE:02526 vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Diagens Biotechnology Co ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hangzhou Diagens Biotechnology Co and its competitors.
Is Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value too high?
Hangzhou Diagens Biotechnology Co's current ROE % Adjusted to Book Value is 0.00%. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value compare to ABT and SYK?
Hangzhou Diagens Biotechnology Co's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. Hangzhou Diagens Biotechnology Co's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score
Get the complete analysis for HKSE:02526
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02526 has been successfully added to your 
